title: Excitotoxicity and metabolic changes in association with infarct progression.
abstract: OBJECTIVE
  We investigated to what extent excitotoxicity and metabolic changes in the peri-infarct region of patients with malignant hemispheric stroke are associated with delayed infarct progression.
  
  
  METHODS
  In 18 patients with malignant hemispheric stroke, 2 microdialysis probes were implanted within the peri-infarct tissue at a distance of 5 and 15 mm to the infarct. Precise probe placement was achieved by intraoperative laser speckle imaging. Glutamate, glucose, pyruvate, and lactate levels were monitored for 5 days after surgery. Delayed infarct progression was determined from serial MRI on the day after surgery and after the monitoring period.
  
  
  RESULTS
  Initial stroke volume ranged from 122 to 479 cm3 with a median of 295 cm3. Nine of 18 patients (50%) had delayed infarct progression (median, 44 cm3; range, 19-93 cm3). In these patients, glucose and individual pyruvate levels were significantly lower when compared with patients without infarct progression, whereas glutamate and the lactate-pyruvate ratio were significantly elevated in patients with infarct progression early after surgery (12-36 hours) at the 15-mm microdialysis probe location. Lactate was elevated but without difference between groups.
  
  
  CONCLUSIONS
  Excitotoxic or metabolic impairment was associated with delayed infarct progression and could serve as a treatment target.
authors.affiliation: From the Department of Neurosurgery (J.W., A.P., N.H., N.S., P.V.), Center for Stroke Research Berlin (J.W., A.P., N.H., N.S., M.S., C.D., J.P.D., P.V.), Departments of Neuroradiology (M.S.) and Neurology (C.D., J.P.D.), Charité-Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Johannes
authors.initials: J
authors.lastname: Woitzik
authors.forename: Alexandra
authors.initials: A
authors.lastname: Pinczolits
authors.forename: Nils
authors.initials: N
authors.lastname: Hecht
authors.forename: Nora
authors.initials: N
authors.lastname: Sandow
authors.forename: Michael
authors.initials: M
authors.lastname: Scheel
authors.forename: Christoph
authors.initials: C
authors.lastname: Drenckhahn
authors.forename: Jens P
authors.initials: JP
authors.lastname: Dreier
authors.forename: Peter
authors.initials: P
authors.lastname: Vajkoczy
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001921:Brain / Q000378:metabolism* / Q000473:pathology; D002544:Cerebral Infarction / Q000378:metabolism* / Q000473:pathology; D018450:Disease Progression; D005260:Female; D005947:Glucose / Q000378:metabolism; D018698:Glutamic Acid / Q000378:metabolism; D005990:Glycerol / Q000378:metabolism; D006801:Humans; D019344:Lactic Acid / Q000378:metabolism; D008297:Male; D017551:Microdialysis / Q000379:methods; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods; D009498:Neurotoxins / Q000378:metabolism*; D019289:Pyruvic Acid / Q000378:metabolism; D020521:Stroke / Q000378:metabolism* / Q000473:pathology
chemical_list: D009498:Neurotoxins; D019344:Lactic Acid; D018698:Glutamic Acid; D019289:Pyruvic Acid; D005947:Glucose; D005990:Glycerol
keywords: glutamic acid; metabolism